Mathematics Behind Evaluating Replimune’s RPx Platform
Replimune is advancing a novel pipeline of oncolytic immunotherapies derived from its RPx platform aimed to fill unmet needs across cancer types. Here’s a breakdown of the mathematical approach using the Venture Capital Method (VCM).
1. Revenue Projections and Market Share
Market Opportunity: To estimate potential revenue, we first identify the Total Addressable Market (TAM) for Replimune’s RPx platform.
Revenue Estimation: Assuming Replimune captures between 1% and 2% of the TAM (assumed to be $250 billion by 2030):
- For a 1% share: 0.01 × 250 billion = 2.5 billion
- For a 2% share: 0.02 × 250 billion = 5 billion
2. Expected Future Value (EFV)
EFV Calculation: Biotech companies are often valued on projected revenue using a multiple:
- For lower revenue ($2.5 billion): EFVlow = 2.5 billion × 5 = 12.5 billion
- For upper revenue ($5 billion): EFVhigh = 5 billion × 10 = 25 billion
3. Discounting for Required Rate of Return
Discounted Present Value (PV): The Venture Capital Method applies a discount rate to reflect risk, often 30% for biotech:
- Lower PV estimate: PVlow = 12.5 billion / (1 + 0.3)5 ≈ 3.17 billion
- Higher PV estimate: PVhigh = 25 billion / (1 + 0.3)5 ≈ 6.34 billion
4. Adjusting for Success Probability
Success Probability Adjustment: Given substantial risks, a success probability of 35% is often applied:
- Adjusted PVlow = 3.17 billion × 0.35 ≈ 1.11 billion
- Adjusted PVhigh = 6.34 billion × 0.35 ≈ 2.22 billion